BioLineRx Ltd. (NASDAQ:BLRX) Sees Large Increase in Short Interest

BioLineRx Ltd. (NASDAQ:BLRX) was the target of a large increase in short interest in April. As of April 15th, there was short interest totalling 783,600 shares, an increase of 32.5% from the March 31st total of 591,500 shares. Based on an average trading volume of 432,700 shares, the days-to-cover ratio is currently 1.8 days.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. PVG Asset Management Corp acquired a new stake in shares of BioLineRx in the fourth quarter valued at about $97,000. NorthRock Partners LLC acquired a new position in shares of BioLineRx in the 4th quarter worth approximately $27,000. B. Riley Wealth Advisors Inc. lifted its holdings in shares of BioLineRx by 88.5% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 21,300 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 10,000 shares during the last quarter. Allen Mooney & Barnes Investment Advisors LLC acquired a new position in shares of BioLineRx in the 3rd quarter worth approximately $46,000. Finally, Rathbones Group PLC acquired a new stake in BioLineRx during the 3rd quarter worth approximately $72,000. Hedge funds and other institutional investors own 1.56% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. StockNews.com upgraded shares of BioLineRx to a “sell” rating in a report on Tuesday, April 23rd. HC Wainwright reissued a “buy” rating and set a $21.00 price objective on shares of BioLineRx in a research report on Wednesday, April 17th.

BioLineRx Price Performance

Shares of NASDAQ BLRX traded up $0.03 during mid-day trading on Monday, hitting $0.64. 339,351 shares of the company’s stock traded hands, compared to its average volume of 401,690. The company’s 50-day moving average is $1.01 and its two-hundred day moving average is $1.30. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.53 and a quick ratio of 1.47. The company has a market capitalization of $51.16 million, a P/E ratio of -0.71 and a beta of 1.38. BioLineRx has a 1 year low of $0.55 and a 1 year high of $2.53.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Thursday, March 28th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. The business had revenue of $4.80 million for the quarter, compared to the consensus estimate of $0.17 million. During the same quarter in the prior year, the business posted ($0.09) earnings per share. On average, equities analysts anticipate that BioLineRx will post -1.03 EPS for the current fiscal year.

About BioLineRx

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.